wsbdaily | Tue, 20 Dec 2022 03:11:24 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
Capricor Therapeutics, Inc.(CAPR)
Capricor Therapeutics, Inc.
10865 Road to the Cure
Suite 150
San Diego, CA 92121
United States
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokin... Read More
Summary & Charts
| Price | $ 4.33 | -0.14 (-3.14%) |
| Day's Range | $ 4.31 - 4.62 | |
| Previous Close | $ 4.47 | |
| Market Cap | $ 112.83M USD | |
| Short Interest % | N/A | |
| Float | N/A | |
| Outstanding | N/A |
| Exchange | NasdaqCM | |
| Industry | Biotechnology | |
| Sector | Healthcare | |
| Volume | 200.17K | |
| Avg. Volume (20 day) | 147.80K | |
| Rel. Volume (20 day) | 1.35 | |
| Rel. Volume (3 month) | 1.10 | |
| Rating | B+ | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | 249.58 % | Strong Buy |
| ROE | -33.21 % | Strong Sell |
| ROA | -13.88 % | Sell |
| P/E | -4.49 % | Strong Sell |
| P/B | 6.86 % | Strong Buy |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Dec 01, 2022 | $ 4.55 | $ 4.62 | $ 4.31 | $ 4.33 | -0.14 | 200,167 | 1.35 | 1.10 | |
| Nov 30, 2022 | $ 4.01 | $ 4.68 | $ 4.01 | $ 4.47 | +0.45 | 423,284 | 2.82 | 2.31 | 2 |
| Nov 29, 2022 | $ 3.90 | $ 4.03 | $ 3.85 | $ 4.02 | +0.08 | 117,807 | 0.87 | 0.64 | |
| Nov 28, 2022 | $ 4.11 | $ 4.22 | $ 3.91 | $ 3.94 | -0.13 | 107,499 | 0.80 | 0.57 | |
| Nov 25, 2022 | $ 4.19 | $ 4.19 | $ 4.01 | $ 4.07 | -0.06 | 48,900 | 0.34 | 0.26 | |
| Nov 23, 2022 | $ 4.12 | $ 4.20 | $ 4.11 | $ 4.13 | +0.07 | 45,501 | 0.31 | 0.24 | |
| Nov 22, 2022 | $ 4.12 | $ 4.19 | $ 4.00 | $ 4.06 | -0.02 | 66,404 | 0.44 | 0.34 | |
| Nov 21, 2022 | $ 4.06 | $ 4.24 | $ 3.97 | $ 4.08 | +0.04 | 110,107 | 0.72 | 0.54 | |
| Nov 18, 2022 | $ 3.92 | $ 4.10 | $ 3.90 | $ 4.04 | +0.17 | 80,003 | 0.52 | 0.40 | |
| Nov 17, 2022 | $ 3.98 | $ 4.00 | $ 3.85 | $ 3.87 | -0.11 | 151,511 | 0.98 | 0.75 | |
| Nov 16, 2022 | $ 4.09 | $ 4.11 | $ 3.93 | $ 3.98 | -0.11 | 172,901 | 1.14 | 0.86 | |
| Nov 15, 2022 | $ 4.18 | $ 4.28 | $ 4.03 | $ 4.09 | -0.05 | 207,001 | 1.38 | 1.04 | |
| Nov 14, 2022 | $ 4.50 | $ 4.57 | $ 4.03 | $ 4.14 | -0.41 | 346,404 | 2.32 | 1.75 | |
| Nov 11, 2022 | $ 4.68 | $ 4.82 | $ 4.47 | $ 4.55 | -0.35 | 205,811 | 1.50 | 1.05 | |
| Nov 10, 2022 | $ 4.68 | $ 4.95 | $ 4.66 | $ 4.90 | +0.19 | 85,907 | 0.62 | 0.44 | |
| Nov 09, 2022 | $ 4.90 | $ 4.90 | $ 4.70 | $ 4.71 | -0.18 | 108,102 | 0.72 | 0.55 | |
| Nov 08, 2022 | $ 4.94 | $ 5.01 | $ 4.85 | $ 4.89 | -0.05 | 59,603 | 0.39 | 0.30 | |
| Nov 07, 2022 | $ 4.96 | $ 5.07 | $ 4.82 | $ 4.94 | -0.01 | 112,301 | 0.71 | 0.56 | |
| Nov 04, 2022 | $ 5.20 | $ 5.20 | $ 4.87 | $ 4.95 | -0.19 | 133,110 | 0.81 | 0.66 | |
| Nov 03, 2022 | $ 5.00 | $ 5.31 | $ 4.92 | $ 5.14 | +0.06 | 173,608 | 0.95 | 0.85 |
News
The latest news about Capricor Therapeutics, Inc. (CAPR).
Seeking Alpha | 2022-11-10 22:21:15
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Alan Leong - BioWatch News Aydin Huseynov - Ladenburg Brian Corday - BullBear Partners Operator Good day, ladies and gentlemen, and welcome to the Capricor Therapeutics Incorporated Third Quarter 2022 Earnings Call. Today's conference is being recorded.
Zacks Investment Research | 2022-11-10 18:48:33
Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire | 2022-11-03 16:01:00
Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET
GlobeNewsWire | 2022-10-06 09:00:00
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present one-year safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD). These data will be featured in a poster presentation at this year's World Muscle Society Congress (WMS) being held both virtually and in Halifax, Nova Scotia, Canada from October 11-15, 2022.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-11-10 | AMC | -0.29 | -0.26 | 10.35% | -- | -- | -- |
| 2022-08-10 | AMC | -0.25 | -0.29 | 16% | -- | -- | -- |
| 2022-05-10 | AMC | -- | -- | -- | -- | -- | -- |
| 2022-03-10 | AMC | -0.19 | -0.26 | 36.84% | -- | -- | -- |
| 2021-11-09 | AMC | -0.22 | -0.17 | 22.73% | 210K | -- | -- |
| 2021-08-12 | AMC | -0.23 | -0.21 | 8.7% | 222K | 204K | -8% |
| 2021-05-13 | AMC | -- | -- | -- | -- | -- | -- |
| 2021-03-11 | AMC | -0.2 | -0.21 | 4.99% | 210K | 58K | -72.47% |
Top Discussions
These are the top discussions over the last 24-hours that mention the CAPR stock ticker symbol.
Unusual Option Activity
Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.
| Type | Strike | Exp Date | DTE | Bid | Ask | Last | Volume | Open Interest | Vol/OI | IV |
|---|---|---|---|---|---|---|---|---|---|---|
| CALL | $ 12.50 | 01/19/23 | 48 | $ 0.00 | $ 0.05 | $ 0.05 | 717 | 467 | 1.54 | 1.38% |
Last Updated: Thu, 1 Dec 2022 22:57 EST
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Tue, 14 Dec 2021 12:00 EST
@wsbdaily
wsbdaily